Market Highlights:
The Global Fabry
Disease Market is expected to grow at a CAGR of 6.8% during the
forecast period. Technological advancements, strong pipeline, advancements in
healthcare facilities, and favorable funding policies are expected to drive the
market growth over the forecast period. Owing to the increasing awareness about
Fabry disease, new and existing market players are coming up with better
treatment approaches. For instance, in 2018, 2018, Amicus Therapeutics launched
Galafold capsules 123mg for the treatment of patients aged 16 years and older with
a confirmed diagnosis of Fabry disease and who have an amenable mutation.
However, diverse range of symptoms, and related complications can restrain the market growth over the assessment period.
Get Free Sample @ https://www.marketresearchfuture.com/sample_request/7064
Regional Analysis:
Geographically, the Americas is expected to dominate the
global market owing to the increasing technological advancements and rising
research and development activities. Gastrointestinal manifestations such as
abdominal pain, diarrhea and nausea are significant burden in a patient with
Fabry disease. So, for the advanced treatment of these patients SmartPill
testing procedure is developed to gain additional understanding of Fabry
disease manifestation via motility abnormalities in order to improve symptom
targeted therapy. This device is currently under clinical trial and the sponsor
of this study is Massachusetts General Hospital.
Europe is expected to hold the second largest market share.
Nearly 2.2 in 10,000 people in the European Union (EU) are affected with Fabry
disease and Fabrazyme (agalsidase beta), Galafold (migalastat) and Replagal
(agalsidase alfa) are the three authorized drugs used for the treatment of
Fabry disease.
Asia-Pacific is expected to be the fastest growing market
owing to the improving healthcare infrastructure.
Moreover, the Middle East and Africa region is expected to
hold the least market share in the global Fabry disease market.
Segmentation:
The Global Fabry Disease Market has been segmented into
type, diagnosis & treatment and end user.
The market, on the basis of type, has been segmented into
type-1 and type-2. The type-2 Fabry disease holds the major market share due to
the high occurrence of type-2 Fabry disease i.e. 1 in 1,500 to 4000 males.
The market, by diagnosis & treatment, has been segmented
into diagnosis and treatment. The diagnosis segment is further classified as
blood test, urine test, thyroid test, lung function test, and imaging. The
imaging segment includes electrocardiogram (EKG), echocardiogram, brain MRI, CT
scan and others. The treatment segment is further classified as enzyme
replacement therapy, gene therapy, pharmaceutical formulations containing
agalsidase alfa, analgesics, anticonvulsants, nonsteroidal anti-inflammatory
drugs (NSAIDs), and others.
The market, by end user, has been segmented into hospitals
& clinics, diagnostic centers, research & academic institutes, and
others.
Key Players:
Some of the prominent players in the global Fabry disease
market are Amgen Inc., Amicus Therapeutics, Inc., AVROBIO, Inc., Idorsia
Pharmaceuticals Ltd, Protalix, Bristol-Myers Squibb Company, GlaxoSmithKline,
iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi,
Shire, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries
Ltd and others.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/fabry-disease-market-7064
About Market Research Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients. Our market research studies by Components,
Application, Logistics and market players for global, regional, and country
level market segments, enable our clients to see more, know more, and do more,
which help to answer all their most important questions.
In order to stay updated
with technology and work process of the industry, MRFR often plans &
conducts meet with the industry experts and industrial visits for its research
analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
Blog: https://healthcarenews12.blogspot.com/
No comments:
Post a Comment